Insights
Insights From Our Experts
Articles
Gene Therapy in Today’s Digital World
Rare diseases are an emerging global public health priority, with a staggering impact on the more than 300 million people worldwide who are living with them. There are more than 6,000 rare diseases, 72% of which…
THINK BEYOND THE THERAPY: Demystifying the Complexities of Cell and Gene Therapy Commercialization
While much attention has been given to the novel science behind cell and gene therapies, ultimately the success of every precision medicine starts and ends with the patient. Whether coordinating a cell or gene therapy clinical…
A YEAR OF ACTION: Why Data-Backed, Integrated Commercialization Strategies Are Must-haves in 2022
By applying transformative commercialization models, nurturing digital transformation and trailblazing in global expansion, we can get therapies to patients around the world who are still waiting for treatment options. For the past two years, the pharmaceutical…
WEBINAR: Reimagining the Patient Journey for CGTs: Informing, Engaging and Empowering the Patient Population
Posted by
Seth Gordon on December 2, 202112/2/21
Cell and gene therapies (CGTs) hold great life-saving and therapeutic advancement potential, but their complexity requires careful approach–starting with engaging and educating patient communities earlier. While the patient’s voice should be a guiding force throughout the…
Webinar: Discover Patient Support Program Needs for Patients with Rare Diseases
In a world where patients face more medication barriers than ever, patient support programs for rare disease patients are critical in providing value-based care that yields a palpable and lasting impact. Manufacturers are acutely aware that…
Getting Treatments to Patients When They Need Them Most: Next Gen Commercialization in Oncology
Commercializing oncology products is extremely complex, but successfully launching new therapies to market is essential for patients and providers in the fight against cancer. In 2020, about 10 million people died from cancer, proving even in…
Driving Commercial Excellence for CAR-T
In this session from the 6th Annual CAR-TCR Summit, Faruk Abdullah, Head of U.S. Consulting, EVERSANA™ MANAGEMENT CONSULTING and Maria Kirsch, SVP & Head of Patient Services share insight on building the future commercialization model designed…
PharmaVOICE Webinar: Next Gen Commercialization Model for Oncology
In a new 60-minute virtual panel, “Next Gen Commercial Models in Oncology,” PharmaVOICE Editor Taren Grom sat down with industry leaders to discuss how changing market dynamics and a rich pipeline in oncology are creating a…
High-Efficiency Commercialization for High-Science Brands
Posted by
Chien Sun, PhD on January 6, 20211/6/21
High-stake or complex therapies, such as cell and gene therapies, immunotherapies and RNA interference (RNAi), have the potential to change the course of treatment for cancer patients and patients with rare diseases. But first, pharma companies must work with providers to navigate patient access complications…
Leadership Briefing – The U.S. Pharmaceutical Market Outlook: The Path to Recovery and the New Normal
During a recent webinar panel, EVERSANA and Reuters gathered industry leaders to discuss the tough questions facing pharma, specifically in the wake of a new U.S. presidency. EVERSANA CEO Jim Lang; Joe Jimenez, Ex-Novartis CEO and…